A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line Treatment for Patients With Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer
Oncologist- United States
doi 10.1634/theoncologist.2017-0664
Full Text
Abstract
Available in
Date
April 25, 2019
Authors
Publisher
Alphamed Press